Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History OVID

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics OVID

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Ovid Therapeutics Inc

OVID
Current price
0.55 USD +0.02 USD (+3.77%)
Last closed 0.48 USD
ISIN US6904691010
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 34 082 784 USD
Yield for 12 month -46.60 %
1Y
3Y
5Y
10Y
15Y
OVID
21.11.2021 - 28.11.2021

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. Address: 441 Ninth Avenue, New York, NY, United States, 10001

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

3.10 USD

P/E Ratio

Dividend Yield

Financials OVID

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures OVID

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+566 000 USD

Last Year

+391 695 USD

Current Quarter

+130 000 USD

Last Quarter

+76 000 USD

Current Year

+566 000 USD

Last Year

-1 205 000 USD

Current Quarter

+130 000 USD

Last Quarter

+76 000 USD
EBITDA -52 900 000 USD
Operating Margin TTM -9 653.85 %
Price to Earnings
Return On Assets TTM -31.37 %
PEG Ratio
Return On Equity TTM -36.31 %
Wall Street Target Price 3.10 USD
Revenue TTM 548 000 USD
Book Value 0.83 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -12.20 %
Dividend Yield
Gross Profit TTM 548 000 USD
Earnings per share -0.34 USD
Diluted Eps TTM -0.34 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation OVID

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 1.79
Enterprise Value Revenue 37.79
Price Sales TTM 62.19
Enterprise Value EBITDA -0.69
Price Book MRQ 0.48

Technical Indicators OVID

For 52 Weeks

0.24 USD 1.47 USD
50 Day MA 0.32 USD
Shares Short Prior Month 2 498 318
200 Day MA 0.68 USD
Short Ratio 3.05
Shares Short 1 240 950
Short Percent 4.20 %